Literature DB >> 22829693

Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.

Junya Abe, Kazushi Izawa, Ryuta Nishikomori, Tomonari Awaya, Tomoki Kawai, Takahiro Yasumi, Naoko Hiragi, Toru Hiragi, Yusei Ohshima, Toshio Heike.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829693     DOI: 10.1093/rheumatology/kes181

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  13 in total

1.  A TREX1 mutation causing cerebral vasculopathy in a patient with familial chilblain lupus.

Authors:  Kazuo Yamashiro; Ryota Tanaka; Yuanzhe Li; Michitaka Mikasa; Nobutaka Hattori
Journal:  J Neurol       Date:  2013-08-30       Impact factor: 4.849

Review 2.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 3.  Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?

Authors:  Christoph Fiehn
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 4.  Human disease phenotypes associated with mutations in TREX1.

Authors:  Gillian I Rice; Mathieu P Rodero; Yanick J Crow
Journal:  J Clin Immunol       Date:  2015-03-04       Impact factor: 8.317

5.  TREX1 - Apex predator of cytosolic DNA metabolism.

Authors:  Sean R Simpson; Wayne O Hemphill; Teesha Hudson; Fred W Perrino
Journal:  DNA Repair (Amst)       Date:  2020-06-12

6.  [Genetics of lupus erythematosus].

Authors:  Claudia Günther
Journal:  Hautarzt       Date:  2015-02       Impact factor: 0.751

7.  The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

Authors:  Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky
Journal:  Ann Rheum Dis       Date:  2022-01-27       Impact factor: 27.973

Review 8.  Therapies in Aicardi-Goutières syndrome.

Authors:  Y J Crow; A Vanderver; S Orcesi; T W Kuijpers; G I Rice
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

9.  TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.

Authors:  C Paradis; M Cadieux-Dion; C Meloche; M Gravel; J Paradis; A Des Roches; G Leclerc; P Cossette; P Begin
Journal:  J Clin Immunol       Date:  2019-01-26       Impact factor: 8.317

Review 10.  Chilblains in Southern California: two case reports and a review of the literature.

Authors:  Rebecca Gordon; Anne M Arikian; Anita S Pakula
Journal:  J Med Case Rep       Date:  2014-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.